Document is current
Any future updates will be listed below
-
Authors
Mamesaya, Nobuaki
Mori, Keita
Kobayashi, Haruki
Omori, Shota
Ko, Ryo
Wakuda, Kazushige
Ono, Akira
Kenmotsu, Hirotsugu
Naito, Tateaki
Murakami, Haruyasu
Takahashi, Toshiaki https://orcid.org/0000-0002-8188-2505
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 23 June 2025
First Online: 6 July 2025
Declarations
:
: N. Mamesaya received grants and personal fees from Boehringer Ingelheim Co., Ltd., MSD K.K., and Chugai Pharmaceutical Co., LTD., grants from Arrivent Biopharma, and personal fees from Novartis Pharma K.K., Taiho Pharmaceutical., AstraZeneca K.K., Bristol-Myers Squibb Japan, and Ono Pharmaceutical Co., LTD. outside the submitted work. H. Kobayashi received personal fees from Eli Lilly K.K., Novartis Pharma K.K., Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. outside the submitted work. S. Omori received grants and personal fees from Daiichi-Sankyo Co., Ltd. and additional personal fees from Chugai Pharmaceutical Co., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Taiho Pharmaceuticals, Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Amgen K.K. outside the submitted work. R. Ko received grants from Boehringer Ingelheim Co., Ltd. and MSD K.K. and personal fees from Boehringer Ingelheim Co., Ltd., Taiho Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., Eli Lilly K.K., Pfizer Inc., and AstraZeneca K.K. outside the submitted work. K. Wakuda received grants and personal fees from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., MSD K.K., and Daiichi Sankyo Co., Ltd. and grants from Novartis Pharma K.K., AbbVie, Amgen K.K., Taiho Pharmaceutical; Boehringer Ingelheim, Eli Lilly K.K., Ono Pharmaceutical, Janssen Pharmaceutical K.K., Takeda Pharmaceutical, and Nihon Kayaku outside of the submitted work. A. Ono received personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. outside of the submitted work. T. Naito received grants from Otsuka Pharmaceutical K.K. and personal fees from Ono Pharmaceutical Co., Ltd. and Helsinn Healthcare SA outside the submitted work. H. Kenmotsu received grants and personal fees from AstraZeneca K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., and Eli Lilly K.K. and personal fees from Amgen K.K., Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Daiichi-Sankyo Co., Ltd., Loxo Oncology, Kyowa Hakko Kirin Co., Ltd., Taiho Pharmaceuticals, Takeda Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., MSD K. K., and Pfizer Inc. outside the submitted work. H. Murakami received grants and personal fees from AstraZeneca K.K., Takeda Pharmaceutical Co., Ltd., AbbVie, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., and IQvia and personal fees from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Japan, MSD K.K., Pfizer Inc., Novartis Pharma K.K., Eli Lilly Japan K.K., Taiho Pharmaceuticals, Boehringer Ingelheim, Eisai, and Nihon Kayaku outside the submitted work. T. Takahashi received grants and personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., MSD, Pfizer Inc., Boehringer Ingelheim, Merck Biopharma Co., Ltd., Amgen K.K., Roche Diagnostics K.K., and Takeda Pharmaceuticals Co., Ltd. and personal fees from Yakult Honsha Co., Ltd. outside the submitted work. The remaining authors declare no conflict of interest.
